Nageshwar Budha

6PUBLICATIONS
45CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Computational methods in fluid flow, heat and mass transfer (incl. computational fluid dynamics)Marketing research methodology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 24, 2026
Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer.

|Feb 11, 2026
Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.

Minjiang Chen, Iurie Bulat, Marina Maglakelidze

|Apr 26, 2025
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact.

Tian Yu, Chi-Yuan Wu, Srikumar Sahasranaman

|Apr 26, 2025
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model-Based Approach.

Ahsan Rizwan, Hugh Giovinazzo, Tian Yu

|Mar 23, 2024
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.

Gerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya

|Mar 22, 2024
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.

Tian Yu, Xiangyu Liu, Chi-Yuan Wu

Pageof 1

Frequent Collaborators

5 joint publications

Tian Yu

3 joint publications

Xiangyu Liu

2 joint publications

Yuying Gao

2 joint publications

Srikumar Sahasranaman